Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) had its price objective increased by HC Wainwright from $8.00 to $11.00 in a research report report published on Friday morning, The Fly reports. HC Wainwright also issued estimates for Alpine Immune Sciences’ Q2 2023 earnings at ($0.35) EPS and Q3 2023 earnings at ($0.39) EPS. Separately, Morgan […]
23.03.2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for ...
Stock Analysts’ price target changes for Friday, March 24th: AirBoss of America (OTCMKTS:ABSSF) had its price target lowered by TD Securities from C$14.00 to C$11.50. Accolade (NASDAQ:ACCD) had its target price raised by Truist Financial Co. to $17.00. Accenture (NYSE:ACN) had its price target boosted by Citigroup Inc. from $300.00 to $310.00. Citigroup Inc. currently […]
RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2... | March 23, 2023
BioNTech is expanding its cancer immunotherapy scope by partnering with OncoC4 on clinical testing of its lead drug. The antibody was designed to offer a safety edge over other CTLA-4-blocking drugs it's on track for a Phase 3 test in non-small cell lung cancer.